Science

Mar 11, 2025, 09:16

Myeloma Paper of the Day, March 11th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Phase II of zanubrutinib + ixazomib/dex in newly diagnosed Waldenström macroglobulinemia finds 4.2% CR and 41.6% VGPR rates; overall, major and deep remission rates 100%, 95.8% and 45.8%; median PFS and OS 40 mos and not reached.”

“Zanubrutinib plus Ixazomib and Dexamethasone in newly diagnosed symptomatic Waldenström macroglobulinemia:a phase II study”

Authors: Wenjie Xiong, Yuting Yan, Tingyu Wang, Lugui Qiu, Shuhua Yi et al.

More posts featuring Robert Orlowski.

cancer ixazomib Lugui Qiu Myeloma Paper of the Day OncoDaily Oncology Robert Orlowski Shuhua Yi Tingyu Wang Waldenström macroglobulinemia Wenjie Xiong Yuting Yan Zanubrutinib

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage